サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1778336

GLP-1アナログの世界市場：適応症別、用途別、流通チャネル別、地域別、機会、予測、2018年～2032年

Global GLP-1 Analogues Market Assessment, By Indication, By Application, By Distribution Channel, By Region, Opportunities and Forecast, 2018-2032F

出版日
ページ情報
英文 244 Pages
納期
3～5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=151.79円
GLP-1アナログの世界市場：適応症別、用途別、流通チャネル別、地域別、機会、予測、2018年～2032年
出版日: 2025年07月29日
発行: Markets & Data
ページ情報: 英文 244 Pages
納期: 3～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のGLP-1アナログの市場規模は、予測期間の2025年～2032年に23.59%のCAGRで拡大し、2024年の416億3,000万米ドルから2032年には2,266億1,000万米ドルに成長すると予測されています。2型糖尿病や肥満などの慢性代謝疾患の管理におけるGLP-1受容体作動薬への依存の高まりが、市場の需要を押し上げています。GLP-1受容体作動薬は、インスリン抵抗性、心血管リスク、肥満に関連する合併症を持つ患者の治療戦略の中核を担っています。

糖尿病有病率の憂慮すべき上昇は、GLP-1アナログ市場の主要な促進要因です。GLP-1アナログ製剤は、特定の患者集団における第二選択薬、あるいは第一選択薬として主要なガイドラインで推奨されており、従来の経口抗糖尿病薬と比較して、優れたHbA1c低下と体重減少をもたらします。また、高リスク患者における主要な心血管系有害事象を減少させる心保護効果もあります。GLP-1アナログ製剤の臨床的価値に対する医師の認識が高まり、処方が大幅に増加しています。GLP-1アナログは、糖尿病と肥満の両疾患を同時に管理することができるため、糖尿病と肥満の両疾患を抱える患者にとって特に有益です。市場の成長は、個別化治療やアウトカムベースの治療へのシフトの高まりによってさらに後押しされており、その中でGLP-1アナログは基幹治療と位置付けられています。

当レポートでは、世界のGLP-1アナログ市場について調査し、市場の概要とともに、適応症別、用途別、流通チャネル別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 米国の関税の影響

第4章 エグゼクティブサマリー

第5章 世界のGLP-1アナログ市場の見通し、2018年～2032年

  • 市場規模分析と予測
  • 市場シェア分析と予測
    • 適応症別
      • デュラグルチド
      • エキセナチド
      • リラグルチド
      • セマグルチド
      • チルゼパチド
      • その他
    • 用途別
      • 2型糖尿病
      • 肥満
      • その他
    • 流通チャネル別
      • 病院
      • 小売薬局
      • オンライン薬局
    • 地域別
      • 北米
      • 欧州
      • アジア太平洋
      • 南米
      • 中東・アフリカ
    • 企業別市場シェア分析（上位5社およびその他- 金額別、2024年）
  • 2024年の市場マップ分析

第6章 北米のGLP-1アナログ市場の見通し、2018年～2032年

  • 市場規模分析と予測
  • 市場シェア分析と予測
  • 国別市場評価
    • 米国
    • カナダ
    • メキシコ

第7章 欧州のGLP-1アナログ市場の見通し、2018年～2032年

  • ドイツ
  • フランス
  • イタリア
  • 英国
  • ロシア
  • オランダ
  • スペイン
  • トルコ
  • ポーランド

第8章 アジア太平洋のGLP-1アナログ市場の見通し、2018年～2032年

  • インド
  • 中国
  • 日本
  • オーストラリア
  • ベトナム
  • 韓国
  • インドネシア
  • フィリピン

第9章 南米のGLP-1アナログ市場の見通し、2018年～2032年

  • ブラジル
  • アルゼンチン

第10章 中東・アフリカのGLP-1アナログ市場の見通し、2018年～2032年

  • サウジアラビア
  • アラブ首長国連邦
  • 南アフリカ

第11章 需要供給分析

第12章 ポーターのファイブフォース分析

第13章 PESTLE分析

第14章 価格分析

第15章 市場力学

  • 市場の促進要因
  • 市場の課題

第16章 市場動向と発展

第17章 臨床パイプラインと医薬品開発

第18章 規制状況

第19章 ケーススタディ

第20章 競合情勢

  • 市場リーダートップ5の競合マトリックス
  • 参入企業トップ5のSWOT分析
  • 市場の主要企業トップ10の情勢
    • Novo Nordisk A/S
    • Eli Lilly and Company
    • Sanofi S.A.
    • AstraZeneca PLC
    • Pfizer Inc.
    • Boehringer Ingelheim International GmbH
    • Amgen Inc.
    • ZEALAND PHARMA A/S
    • Merck & Co., Inc.
    • Hanmi Pharm.Co.,Ltd.

第21章 戦略的提言

第22章 調査会社について・免責事項

図表

List of Tables

  • Table 1. Competition Matrix of Top 5 Market Leaders
  • Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global GLP-1 Analogues Market, By Value, In USD Billion, 2018-2032F
  • Figure 2. Global GLP-1 Analogues Market Share (%), By Indication, 2018-2032F
  • Figure 3. Global GLP-1 Analogues Market Share (%), By Application, 2018-2032F
  • Figure 4. Global GLP-1 Analogues Market Share (%), By Distribution Channel, 2018-2032Fs
  • Figure 5. Global GLP-1 Analogues Market Share (%), By Region, 2018-2032F
  • Figure 6. North America GLP-1 Analogues Market, By Value, In USD Billion, 2018-2032F
  • Figure 7. North America GLP-1 Analogues Market Share (%), By Indication, 2018-2032F
  • Figure 8. North America GLP-1 Analogues Market Share (%), By Application, 2018-2032F
  • Figure 9. North America GLP-1 Analogues Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 10. North America GLP-1 Analogues Market Share (%), By Country, 2018-2032F
  • Figure 11. United States GLP-1 Analogues Market, By Value, In USD Billion, 2018-2032F
  • Figure 12. United States GLP-1 Analogues Market Share (%), By Indication, 2018-2032F
  • Figure 13. United States GLP-1 Analogues Market Share (%), By Application, 2018-2032F
  • Figure 14. United States GLP-1 Analogues Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 15. Canada GLP-1 Analogues Market, By Value, In USD Billion, 2018-2032F
  • Figure 16. Canada GLP-1 Analogues Market Share (%), By Indication, 2018-2032F
  • Figure 17. Canada GLP-1 Analogues Market Share (%), By Application, 2018-2032F
  • Figure 18. Canada GLP-1 Analogues Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 19. Mexico GLP-1 Analogues Market, By Value, In USD Billion, 2018-2032F
  • Figure 20. Mexico GLP-1 Analogues Market Share (%), By Indication, 2018-2032F
  • Figure 21. Mexico GLP-1 Analogues Market Share (%), By Application, 2018-2032F
  • Figure 22. Mexico GLP-1 Analogues Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 23. Europe GLP-1 Analogues Market, By Value, In USD Billion, 2018-2032F
  • Figure 24. Europe GLP-1 Analogues Market Share (%), By Indication, 2018-2032F
  • Figure 25. Europe GLP-1 Analogues Market Share (%), By Application, 2018-2032F
  • Figure 26. Europe GLP-1 Analogues Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 27. Europe GLP-1 Analogues Market Share (%), By Country, 2018-2032F
  • Figure 28. Germany GLP-1 Analogues Market, By Value, In USD Billion, 2018-2032F
  • Figure 29. Germany GLP-1 Analogues Market Share (%), By Indication, 2018-2032F
  • Figure 30. Germany GLP-1 Analogues Market Share (%), By Application, 2018-2032F
  • Figure 31. Germany GLP-1 Analogues Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 32. France GLP-1 Analogues Market, By Value, In USD Billion, 2018-2032F
  • Figure 33. France GLP-1 Analogues Market Share (%), By Indication, 2018-2032F
  • Figure 34. France GLP-1 Analogues Market Share (%), By Application, 2018-2032F
  • Figure 35. France GLP-1 Analogues Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 36. Italy GLP-1 Analogues Market, By Value, In USD Billion, 2018-2032F
  • Figure 37. Italy GLP-1 Analogues Market Share (%), By Indication, 2018-2032F
  • Figure 38. Italy GLP-1 Analogues Market Share (%), By Application, 2018-2032F
  • Figure 39. Italy GLP-1 Analogues Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 40. United Kingdom GLP-1 Analogues Market, By Value, In USD Billion, 2018-2032F
  • Figure 41. United Kingdom GLP-1 Analogues Market Share (%), By Indication, 2018-2032F
  • Figure 42. United Kingdom GLP-1 Analogues Market Share (%), By Application, 2018-2032F
  • Figure 43. United Kingdom GLP-1 Analogues Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 44. Russia GLP-1 Analogues Market, By Value, In USD Billion, 2018-2032F
  • Figure 45. Russia GLP-1 Analogues Market Share (%), By Indication, 2018-2032F
  • Figure 46. Russia GLP-1 Analogues Market Share (%), By Application, 2018-2032F
  • Figure 47. Russia GLP-1 Analogues Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 48. Netherlands GLP-1 Analogues Market, By Value, In USD Billion, 2018-2032F
  • Figure 49. Netherlands GLP-1 Analogues Market Share (%), By Indication, 2018-2032F
  • Figure 50. Netherlands GLP-1 Analogues Market Share (%), By Application, 2018-2032F
  • Figure 51. Netherlands GLP-1 Analogues Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 52. Spain GLP-1 Analogues Market, By Value, In USD Billion, 2018-2032F
  • Figure 53. Spain GLP-1 Analogues Market Share (%), By Indication, 2018-2032F
  • Figure 54. Spain GLP-1 Analogues Market Share (%), By Application, 2018-2032F
  • Figure 55. Spain GLP-1 Analogues Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 56. Turkey GLP-1 Analogues Market, By Value, In USD Billion, 2018-2032F
  • Figure 57. Turkey GLP-1 Analogues Market Share (%), By Indication, 2018-2032F
  • Figure 58. Turkey GLP-1 Analogues Market Share (%), By Application, 2018-2032F
  • Figure 59. Turkey GLP-1 Analogues Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 60. Poland GLP-1 Analogues Market, By Value, In USD Billion, 2018-2032F
  • Figure 61. Poland GLP-1 Analogues Market Share (%), By Indication, 2018-2032F
  • Figure 62. Poland GLP-1 Analogues Market Share (%), By Application, 2018-2032F
  • Figure 63. Poland GLP-1 Analogues Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 64. South America GLP-1 Analogues Market, By Value, In USD Billion, 2018-2032F
  • Figure 65. South America GLP-1 Analogues Market Share (%), By Indication, 2018-2032F
  • Figure 66. South America GLP-1 Analogues Market Share (%), By Application, 2018-2032F
  • Figure 67. South America GLP-1 Analogues Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 68. South America GLP-1 Analogues Market Share (%), By Country, 2018-2032F
  • Figure 69. Brazil GLP-1 Analogues Market, By Value, In USD Billion, 2018-2032F
  • Figure 70. Brazil GLP-1 Analogues Market Share (%), By Indication, 2018-2032F
  • Figure 71. Brazil GLP-1 Analogues Market Share (%), By Application, 2018-2032F
  • Figure 72. Brazil GLP-1 Analogues Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 73. Argentina GLP-1 Analogues Market, By Value, In USD Billion, 2018-2032F
  • Figure 74. Argentina GLP-1 Analogues Market Share (%), By Indication, 2018-2032F
  • Figure 75. Argentina GLP-1 Analogues Market Share (%), By Application, 2018-2032F
  • Figure 76. Argentina GLP-1 Analogues Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 77. Asia-Pacific GLP-1 Analogues Market, By Value, In USD Billion, 2018-2032F
  • Figure 78. Asia-Pacific GLP-1 Analogues Market Share (%), By Indication, 2018-2032F
  • Figure 79. Asia-Pacific GLP-1 Analogues Market Share (%), By Application, 2018-2032F
  • Figure 80. Asia-Pacific GLP-1 Analogues Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 81. Asia-Pacific GLP-1 Analogues Market Share (%), By Country, 2018-2032F
  • Figure 82. India GLP-1 Analogues Market, By Value, In USD Billion, 2018-2032F
  • Figure 83. India GLP-1 Analogues Market Share (%), By Indication, 2018-2032F
  • Figure 84. India GLP-1 Analogues Market Share (%), By Application, 2018-2032F
  • Figure 85. India GLP-1 Analogues Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 86. China GLP-1 Analogues Market, By Value, In USD Billion, 2018-2032F
  • Figure 87. China GLP-1 Analogues Market Share (%), By Indication, 2018-2032F
  • Figure 88. China GLP-1 Analogues Market Share (%), By Application, 2018-2032F
  • Figure 89. China GLP-1 Analogues Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 90. Japan GLP-1 Analogues Market, By Value, In USD Billion, 2018-2032F
  • Figure 91. Japan GLP-1 Analogues Market Share (%), By Indication, 2018-2032F
  • Figure 92. Japan GLP-1 Analogues Market Share (%), By Application, 2018-2032F
  • Figure 93. Japan GLP-1 Analogues Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 94. Australia GLP-1 Analogues Market, By Value, In USD Billion, 2018-2032F
  • Figure 95. Australia GLP-1 Analogues Market Share (%), By Indication, 2018-2032F
  • Figure 96. Australia GLP-1 Analogues Market Share (%), By Application, 2018-2032F
  • Figure 97. Australia GLP-1 Analogues Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 98. Vietnam GLP-1 Analogues Market, By Value, In USD Billion, 2018-2032F
  • Figure 99. Vietnam GLP-1 Analogues Market Share (%), By Indication, 2018-2032F
  • Figure 100. Vietnam GLP-1 Analogues Market Share (%), By Application, 2018-2032F
  • Figure 101. Vietnam GLP-1 Analogues Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 102. South Korea GLP-1 Analogues Market, By Value, In USD Billion, 2018-2032F
  • Figure 103. South Korea GLP-1 Analogues Market Share (%), By Indication, 2018-2032F
  • Figure 104. South Korea GLP-1 Analogues Market Share (%), By Application, 2018-2032F
  • Figure 105. South Korea GLP-1 Analogues Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 106. Indonesia GLP-1 Analogues Market, By Value, In USD Billion, 2018-2032F
  • Figure 107. Indonesia GLP-1 Analogues Market Share (%), By Indication, 2018-2032F
  • Figure 108. Indonesia GLP-1 Analogues Market Share (%), By Application, 2018-2032F
  • Figure 109. Indonesia GLP-1 Analogues Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 110. Philippines GLP-1 Analogues Market, By Value, In USD Billion, 2018-2032F
  • Figure 111. Philippines GLP-1 Analogues Market Share (%), By Indication, 2018-2032F
  • Figure 112. Philippines GLP-1 Analogues Market Share (%), By Application, 2018-2032F
  • Figure 113. Philippines GLP-1 Analogues Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 114. Middle East & Africa GLP-1 Analogues Market, By Value, In USD Billion, 2018-2032F
  • Figure 115. Middle East & Africa GLP-1 Analogues Market Share (%), By Indication, 2018-2032F
  • Figure 116. Middle East & Africa GLP-1 Analogues Market Share (%), By Application, 2018-2032F
  • Figure 117. Middle East & Africa GLP-1 Analogues Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 118. Middle East & Africa GLP-1 Analogues Market Share (%), By Country, 2018-2032F
  • Figure 119. Saudi Arabia GLP-1 Analogues Market, By Value, In USD Billion, 2018-2032F
  • Figure 120. Saudi Arabia GLP-1 Analogues Market Share (%), By Indication, 2018-2032F
  • Figure 121. Saudi Arabia GLP-1 Analogues Market Share (%), By Application, 2018-2032F
  • Figure 122. Saudi Arabia GLP-1 Analogues Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 123. UAE GLP-1 Analogues Market, By Value, In USD Billion, 2018-2032F
  • Figure 124. UAE GLP-1 Analogues Market Share (%), By Indication, 2018-2032F
  • Figure 125. UAE GLP-1 Analogues Market Share (%), By Application, 2018-2032F
  • Figure 126. UAE GLP-1 Analogues Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 127. South Africa GLP-1 Analogues Market, By Value, In USD Billion, 2018-2032F
  • Figure 128. South Africa GLP-1 Analogues Market Share (%), By Indication, 2018-2032F
  • Figure 129. South Africa GLP-1 Analogues Market Share (%), By Application, 2018-2032F
  • Figure 130. South Africa GLP-1 Analogues Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 131. By Indication Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 132. By Application Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 133. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 134. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2024
目次
Product Code: MX13767

Global GLP-1 analogues market is projected to witness a CAGR of 23.59% during the forecast period 2025-2032, growing from USD 41.63 billion in 2024 to USD 226.61 billion in 2032. The increasing reliance on GLP-1 receptor agonists for managing chronic metabolic conditions such as type 2 diabetes and obesity is bolstering the market's demand. These drugs are central to the therapeutic strategy for patients with insulin resistance, cardiovascular risk, and obesity-related complications.

The alarming rise in diabetes prevalence is a key driver of the GLP-1 analogues market. GLP-1 analogues, recommended by leading guidelines as a second-line or even first-line therapy in specific patient populations, offer superior HbA1c reduction and weight loss when compared to traditional oral antidiabetics. They also provide cardioprotective benefits, reducing major adverse cardiovascular events in high-risk patients. Growing awareness among physicians about the clinical value of GLP-1 analogues is resulting in a significant increase in prescriptions. Patients with both diabetes and obesity are particularly benefiting from these medications, as they help manage both conditions concurrently. The market's growth is further supported by the increasing shift toward personalized and outcomes-based treatments, in which GLP-1 analogues are considered cornerstone therapy.

Increasing Investments in Research Activities Boost Market Growth

Increasing investments in research activities are a key driver of growth in the global GLP-1 analogues market, which is projected to expand significantly in the coming years. These investments facilitate the development of innovative GLP-1 analogue drugs with enhanced efficacy, safety, and delivery methods, including oral formulations and combination therapies. Research efforts are also expanding the therapeutic applications of GLP-1 analogues beyond type 2 diabetes to include obesity, nonalcoholic steatohepatitis (NASH), Alzheimer's disease, and cardiovascular conditions. This broadening pipeline of indications attracts more patients and healthcare providers, fueling market demand. Additionally, ongoing clinical trials and patent-protected novel molecules from leading companies, such as Novo Nordisk A/S and Eli Lilly and Company, strengthen their market dominance and create high entry barriers for competitors. For instance, in August 2024, Eli Lilly and Company announced positive results from the SURMOUNT-1 Phase 3 trial showing that weekly injections of tirzepatide reduced the risk of developing type 2 diabetes by 94% in adults with pre-diabetes and obesity or overweight. Tirzepatide's dual action on GIP and GLP-1 receptors helps regulate appetite and insulin secretion, contributing to sustained weight loss and improved metabolic health. The study also confirmed a favourable safety profile, with mostly mild to moderate gastrointestinal side effects. These findings highlight tirzepatide's potential as a long-term therapy to prevent type 2 diabetes in high-risk populations. The focus on personalised medicine and enhanced patient outcomes through research further accelerates the adoption of this approach worldwide.

Strategic Collaborations Support Market Expansion

Innovation in GLP-1 analogues is accelerating, with pharmaceutical companies investing heavily in next-generation molecules and delivery platforms. Key developments include oral formulations, once-monthly dosing schedules, and dual or triple agonists that target multiple incretin pathways for enhanced efficacy. Companies are also exploring fixed-dose combinations of SGLT2 inhibitors, basal insulin, and other antidiabetics to offer more comprehensive glycemic control through collaborations and partnerships. Strategic partnerships and licensing agreements are reshaping the competitive landscape. Leading market players are teaming up with biotech companies to co-develop and commercialize promising candidates. For instance, in January 2024, Novo Nordisk A/S collaborated with two biotech companies, Cellarity Inc. and Omega Therapeutics, Inc., to develop new treatments for patients with obesity, cardiometabolic disorders, and liver diseases. This trend is also facilitating faster market entry into emerging economies through local manufacturing and distribution agreements.

Obesity Witnesses Rapid Market Growth

The ability of GLP-1 receptor agonists to promote weight loss has led to a significant paradigm shift in obesity pharmacotherapy. Increasing recognition of obesity as a disease requiring medical treatment, rather than solely lifestyle changes, is transforming the therapeutic landscape. Due to the rising incidences of obesity, the market is witnessing a significant increase in demand. As per the estimates of the Centres for Disease Control and Prevention, more than 2 in 5 adults in the United States have obesity. Governments, employers, and payers are acknowledging the long-term economic burden of untreated obesity, leading to broader reimbursement coverage in some regions. As public health policies begin to include funding for anti-obesity drugs, demand for GLP-1 analogues is expected to increase. Additionally, the launch of long-acting and oral variants has improved accessibility, particularly for patients averse to frequent injections, providing lucrative growth opportunities for the market.

North America Holds a Major Market Share

North America currently dominates the global GLP-1 analogues market, supported by a high prevalence of diabetes and obesity, favourable reimbursement policies, and strong healthcare infrastructure. As per the estimates of the government of Canada, approximately 9.6% of the country's population is diagnosed with diabetes. The presence of major manufacturers and the rapid adoption of new therapies have solidified the region's position. Direct-to-consumer advertising and increasing physician awareness also contribute to high prescription volumes.

Meanwhile, Asia-Pacific is expected to grow at the fastest pace over the forecast period. This growth is driven by rising urbanization, sedentary lifestyles, and dietary changes that have led to increased rates of metabolic disorders. Government initiatives for universal health coverage and access to diabetes treatment in countries such as India, China, and Indonesia are expanding the patient base. As local regulators fast-track approvals and multinational companies enter into licensing agreements, the market is witnessing significant growth opportunities in the region.

Impact of the U.S. Tariff on Global GLP-1 Analogues Market

The recent wave of U.S. tariffs on pharmaceuticals, including GLP-1 analogues such as Ozempic and Wegovy, is significantly disrupting the global market. These tariffs on imported active pharmaceutical ingredients (APIs) from countries such as Denmark, Ireland, China, and India are driving up production costs. While brand companies may temporarily absorb extra costs, generics and smaller API manufacturers, which operate on thin margins, are most vulnerable. This may lead to price hikes, supply shortages, and even some vendors exiting the market in the United States. Insurance premiums could also rise in the country and underinsured patients may lose access to these vital therapies.

Key Players Landscape and Outlook

The key players in the market are focusing on expanding their geographical presence to improve their market positioning. For instance, in March 2025, Eli Lilly and Company launched its obesity management drug, Mounjaro, in India. The injection is administered once a week and targets both GIP and GLP-1 receptors, offering significant weight loss and blood sugar control. Currently, the company aims to expand access to the drug without forming local partnerships. Its affordability and flexible dosing make it competitive against existing drugs including semaglutide, accelerating market penetration in India, which has millions affected by metabolic diseases. This strategic launch supports global market growth by increasing adoption in emerging markets and setting new standards for GLP-1 therapies worldwide.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Impact of U.S. Tariffs

4. Executive Summary

5. Global GLP-1 Analogues Market Outlook, 2018-2032F

  • 5.1. Market Size Analysis & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share Analysis & Forecast
    • 5.2.1. By Indication
      • 5.2.1.1. Dulaglutide
      • 5.2.1.2. Exenatide
      • 5.2.1.3. Liraglutide
      • 5.2.1.4. Semaglutide
      • 5.2.1.5. Tirzepatide
      • 5.2.1.6. Others
    • 5.2.2. By Application
      • 5.2.2.1. Type 2 Diabetes
      • 5.2.2.2. Obesity
      • 5.2.2.3. Others
    • 5.2.3. By Distribution Channel
      • 5.2.3.1. Hospitals
      • 5.2.3.2. Retail Pharmacies
      • 5.2.3.3. Online Pharmacies
    • 5.2.4. By Region
      • 5.2.4.1. North America
      • 5.2.4.2. Europe
      • 5.2.4.3. Asia-Pacific
      • 5.2.4.4. South America
      • 5.2.4.5. Middle East and Africa
    • 5.2.5. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
  • 5.3. Market Map Analysis, 2024
    • 5.3.1. By Indication
    • 5.3.2. By Application
    • 5.3.3. By Distribution Channel
    • 5.3.4. By Region

6. North America GLP-1 Analogues Market Outlook, 2018-2032F

  • 6.1. Market Size Analysis & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share Analysis & Forecast
    • 6.2.1. By Indication
      • 6.2.1.1. Dulaglutide
      • 6.2.1.2. Exenatide
      • 6.2.1.3. Liraglutide
      • 6.2.1.4. Semaglutide
      • 6.2.1.5. Tirzepatide
      • 6.2.1.6. Others
    • 6.2.2. By Application
      • 6.2.2.1. Type 2 Diabetes
      • 6.2.2.2. Obesity
      • 6.2.2.3. Others
    • 6.2.3. By Distribution Channel
      • 6.2.3.1. Hospitals
      • 6.2.3.2. Retail Pharmacies
      • 6.2.3.3. Online Pharmacies
    • 6.2.4. By Country Share
      • 6.2.4.1. United States
      • 6.2.4.2. Canada
      • 6.2.4.3. Mexico
  • 6.3. Country Market Assessment
    • 6.3.1. United States GLP-1 Analogues Market Outlook, 2018-2032F*
      • 6.3.1.1. Market Size Analysis & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share Analysis & Forecast
        • 6.3.1.2.1. By Indication
          • 6.3.1.2.1.1. Dulaglutide
          • 6.3.1.2.1.2. Exenatide
          • 6.3.1.2.1.3. Liraglutide
          • 6.3.1.2.1.4. Semaglutide
          • 6.3.1.2.1.5. Tirzepatide
          • 6.3.1.2.1.6. Others
        • 6.3.1.2.2. By Application
          • 6.3.1.2.2.1. Type 2 Diabetes
          • 6.3.1.2.2.2. Obesity
          • 6.3.1.2.2.3. Others
        • 6.3.1.2.3. By Distribution Channel
          • 6.3.1.2.3.1. Hospitals
          • 6.3.1.2.3.2. Retail Pharmacies
          • 6.3.1.2.3.3. Online Pharmacies
    • 6.3.2. Canada
    • 6.3.3. Mexico

All segments will be provided for all regions and countries covered

7. Europe GLP-1 Analogues Market Outlook, 2018-2032F

  • 7.1. Germany
  • 7.2. France
  • 7.3. Italy
  • 7.4. United Kingdom
  • 7.5. Russia
  • 7.6. Netherlands
  • 7.7. Spain
  • 7.8. Turkey
  • 7.9. Poland

8. Asia-Pacific GLP-1 Analogues Market Outlook, 2018-2032F

  • 8.1. India
  • 8.2. China
  • 8.3. Japan
  • 8.4. Australia
  • 8.5. Vietnam
  • 8.6. South Korea
  • 8.7. Indonesia
  • 8.8. Philippines

9. South America GLP-1 Analogues Market Outlook, 2018-2032F

  • 9.1. Brazil
  • 9.2. Argentina

10. Middle East and Africa GLP-1 Analogues Market Outlook, 2018-2032F

  • 10.1. Saudi Arabia
  • 10.2. UAE
  • 10.3. South Africa

11. Demand Supply Analysis

12. Porter's Five Forces Analysis

13. PESTLE Analysis

14. Pricing Analysis

15. Market Dynamics

  • 15.1. Market Drivers
  • 15.2. Market Challenges

16. Market Trends and Developments

17. Clinical Pipeline & Drug Development

18. Regulatory Landscape

19. Case Studies

20. Competitive Landscape

  • 20.1. Competition Matrix of Top 5 Market Leaders
  • 20.2. SWOT Analysis for Top 5 Players
  • 20.3. Key Players Landscape for Top 10 Market Players
    • 20.3.1. Novo Nordisk A/S
      • 20.3.1.1. Company Details
      • 20.3.1.2. Key Management Personnel
      • 20.3.1.3. Products and Services
      • 20.3.1.4. Financials (As Reported)
      • 20.3.1.5. Key Market Focus and Geographical Presence
      • 20.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
    • 20.3.2. Eli Lilly and Company
    • 20.3.3. Sanofi S.A.
    • 20.3.4. AstraZeneca PLC
    • 20.3.5. Pfizer Inc.
    • 20.3.6. Boehringer Ingelheim International GmbH
    • 20.3.7. Amgen Inc.
    • 20.3.8. ZEALAND PHARMA A/S
    • 20.3.9. Merck & Co., Inc.
    • 20.3.10. Hanmi Pharm.Co.,Ltd.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

21. Strategic Recommendations

22. About Us and Disclaimer